TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06328491
Drug: Erdafitinib
Normalized name: erdafitinib
DrugBank: Erdafitinib (DB12147)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Protein Kinase Inhibitor
Study: NCT05167760
Drug: Apraclonidine
Normalized name: Apraclonidine
DrugBank: Apraclonidine (DB00964)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-2 drops per eye every 8 hours for 2 weeks
Study: NCT05839470
Drug: cadonilimab
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadonilimab (6mg/kg, iv, Q2W, Day1)
Study: NCT05839470
Drug: irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: irinotecan\* 165 mg/m² iv continue for 1.5 hours, D1
Study: NCT05839470
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oxaliplatin 85 mg/m² iv continue for 2 hours,
Study: NCT05839470
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU 2400 mg/m² cont. inf. 46h
Study: NCT05926700
Drug: Candonilimab
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients were treated with Candonilimab + anlotinib, with Cadonilimab 10mg/kg, D1 administration; Anlotinib 12mg/ day was orally administered for 2 weeks and stopped for a week, with 21 days as a course of treatment.
Study: NCT06383078
Drug: Folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Folinic acid 400 mg/\^2 D1
Study: NCT06383078
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU 2400 mg/\^2 D1 IV continuous infusion over 46 hours
Study: NCT05177991
Drug: Liposomal Bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20cc of Liposomal Bupivacaine for TAP block
Study: NCT05177991
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20cc of Bupivacaine for TAP block
Study: NCT04524910
Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: As prescribed by the treating physician
Study: NCT05013372
Drug: CD147- CAR T cells
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAR T cells targeting CD147
Study: NCT00939497
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT05352919
Drug: Litifilimab
Normalized name: Litifilimab
DrugBank: Litifilimab (DB18864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT05352919
Drug: Litifilimab-matching placebo
DrugBank: Litifilimab (DB18864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT04666714
Drug: Pregabalin 75mg
Normalized name: PREGABALIN 75MG CAP,UD
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 75mg tablet
Study: NCT04666714
Drug: Pregabalin 150mg
Normalized name: PREGABALIN 150MG CAP,UD
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 150mg tablet
Study: NCT05410301
Drug: Lomustine
Normalized name: Lomustine
DrugBank: Lomustine (DB01206)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy drug
Study: NCT05410301
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemotherapy and targeted therapy drug
Study: NCT04945070
Drug: MDI - Multiple dose insulin injection
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuing with established MDI regimen
Study: NCT06190067
Drug: Azacitidine Plus PD-1 therapy
Normalized name: Recombinant pd-1 mab cs1003
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients were treated by Azacytidine(75 mg/m2 subcutaneous injection qd on days 1-7) plus PD-1 therapy(200mg iv qd d8)
Study: NCT01870102
Drug: Pelubiprofen IR (Pelubiprofen 30mg) TID
Normalized name: Flurbiprofen
DrugBank: Pelubiprofen (DB12150)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01870102
Drug: Pelubiprofen SR (Pelubiprofen 45 mg) BID
Normalized name: Flurbiprofen
DrugBank: Pelubiprofen (DB12150)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04878003
Drug: TL-895
Normalized name: TL-895
DrugBank: TL-895 (DB16471)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TL-895, administration by mouth
Study: NCT05349929
Drug: Gelofen (generic name of Ibuprofen in Iran)
Normalized name: Gablofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gelofen capsules, 400mg Ibuprofen, Dana pharma company, every 6hours
Study: NCT04721795
Drug: Atorvastatin with standard anti tuberculosis drugs
Normalized name: Mycobacterium tuberculosis
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive oral 30/40mg of atorvastatin daily for 2 months together with oral doses of standard antituberculosis drugs consisting of Rifampicin, INH, Ethambuthol and pyrazinamide for 2months. At the end of 2months, participants will continue with only standard anti tuberculosis drugs, Rifampicin and INH for 4months.Doseage of antituberculosis drugs are dependent on weight
Study: NCT04564339
Drug: Ravulizumab
Normalized name: ravulizumab
DrugBank: Ravulizumab (DB11580)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dosages (loading and maintenance) will be based on the participant's body weight.
Study: NCT04937387
Drug: FF/VI
Normalized name: Fluticasone Furoate/Vilanterol
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: FF/VI will be administered.
Study: NCT04190550
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04190550
Drug: Idarubicin Hydrochloride
Normalized name: Idarubicin Hydrochloride
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04190550
Drug: Navtemadlin
Normalized name: Navtemadlin
DrugBank: Navtemadlin (DB15299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06180278
Drug: Inebilizumab
Normalized name: INEBILIZUMAB
DrugBank: Inebilizumab (DB12530)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants with NMOSD who previously enrolled in N-MOmentum study, who participated for at least 2 years in the open label phase (OLP) of the study, and participants newly initiating inebilizumab treatment at the discretion of their treating physician will have hematology, chemistry, B-cell count, serum immunoglobulin (Ig) levels, adverse events, concomitant medications list, NMOSD attacks information, antidrug antibody (ADA) status and titers collected.
Study: NCT05900635
Drug: Lactoferrin
Normalized name: Lactoferrin
DrugBank: Lactoferrin (DB16555)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effect of adding Lactoferrin to Oral Iron Supplementation for the treatment of Iron Deficiency Anemia in Chronic Kidney Disease Patients
Study: NCT05900635
Drug: Ferrous Glycine Sulfate
Normalized name: Ferrous glycine sulfate
DrugBank: Ferrous glycine sulfate (DB14501)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effect of adding Lactoferrin to Oral Iron Supplementation for the treatment of Iron Deficiency Anemia in Chronic Kidney Disease Patients
Study: NCT04624711
Drug: Eribulin Mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eribulin mesylate 1.4mg/m2, administered intravenously on Days 1 and 8 of each 21 day cycle.
Study: NCT04624711
Drug: Anlotinib hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib 12mg, administered orally on Days 1-14 of each 21 day cycle.
Study: NCT04931784
Drug: Nitrate
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of intra-coronary nitrate before percutaneous coronary intervention
Study: NCT06441097
Drug: Polatuzumab vedotin
Normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.
Study: NCT06441097
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
Study: NCT06441097
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone PO will be administered as per the schedule specified in the respective arm.
Study: NCT06441097
Drug: Acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Acalabrutinib PO will be administered as per the schedule specified in the respective arm.
Study: NCT06441097
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide PO will be administered as per the schedule specified in the respective arm.
Study: NCT06441097
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine IV infusion will be administered as per the schedule specified in the respective arm.
Study: NCT05731895
Drug: BI 425809 (iclepertin)
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 425809 (iclepertin)
Study: NCT00001014
Drug: Trimetrexate glucuronate
Normalized name: Trimetrexate Glucuronate
DrugBank: Trimetrexate (DB01157)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001014
Drug: Sulfamethoxazole-Trimethoprim
Normalized name: sulfamethoxazole-trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05417230
Drug: RC48-ADC
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5mg/kg, IV, d1, every 2 weeks;
Study: NCT05417230
Drug: Envafolimab
Normalized name: Envafolimab
DrugBank: Envafolimab (DB15769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg, SC, d1, every 2 weeks;
Study: NCT05197426
Drug: Oral Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days
Study: NCT05023486
Drug: NP-G2-044 Monotherapy
Normalized name: NP-G2-044
DrugBank: NP-G2-044 (DB14995)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600 mg QD, 2000mg QD, and 2100 mg QD
Study: NCT05023486
Drug: NP-G2-044 Combination therapy
Normalized name: NP-G2-044
DrugBank: NP-G2-044 (DB14995)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600 mg QD or 2100 mg QD
Study: NCT04833907
Drug: rAAV-Olig001-ASPA
Normalized name: rAAV-Olig001-ASPA
DrugBank: MYR-101 (DB17075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracerebroventricular administration of a single dose
Study: NCT04833907
Drug: Levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Keppra daily dose (20-50 mg/kg/day divided twice daily administered orally or per G-tube) in the post-operative period and continued for 3 months per standard of care to prevent seizure activity.
Study: NCT04833907
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Post-operatively, a 3-month steroid taper is planned to prevent or reduce possible delayed immunological responses. This tapering regimen will consist of 0.5 mg/kg/day prednisone during weeks 1-4; followed by 0.3 mg/kg/day prednisone during weeks 5-8; and 0.1mg prednisone during weeks 9-12, then off. If there is evidence of new inflammation on MRI at 3-months on T2 FLAIR, the steroid taper will be extended for an additional 3 months or we will transition to steroid-sparing immunosuppression.
Study: NCT06118047
Drug: Crisaborole Ointment
Normalized name: Crisaborole Ointment
DrugBank: Crisaborole (DB05219)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Crisaborole ointment to be applied twice daily.
Study: NCT06118047
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab
Study: NCT04955743
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg intravenous (IV) is administered every 3 weeks
Study: NCT04955743
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 20 mg orally (PO) is administered daily
Study: NCT06366724
Drug: Pyridostigmine
Normalized name: Pyridostigmine
DrugBank: Pyridostigmine (DB00545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyridostigmine timeline:~Weeks 0-2: 20mg TID (1.67 mL TID)~Weeks 2-4: 40mg TID (3.33 mL TID)~Weeks 5-13: 60mg TID (5mL TID)
Study: NCT05147272
Drug: RP-6306 (oral PKMYT1 inhibitor)
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RP-6306 in combination with gemcitabine
Study: NCT06226350
Drug: Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection
Normalized name: Anti-VEGF Humanized Monoclonal Antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: F520,IV, 3mg/kg every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.
Study: NCT06366724
Drug: Low-Dose Naltrexone
Normalized name: ethinyl estradiol
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LDN timeline:~Weeks 0-2: 1.5mg QD (1.5mL QD)~Weeks 2-4: 3.0mg QD (3.0mL QD)~Weeks 5-13: 4.5mg QD (4.5mL QD)
Study: NCT04872166
Drug: BTX-A51
Normalized name: BTX-A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: One 28 day cycle of treatment will consist of 4 weeks of treatment with a weekly dosing schedule of up to 5 days per weekf.
Study: NCT04939597
Drug: Memantine Hydrochloride
Normalized name: Memantine Hydrochloride
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT06482853
Drug: Angiotensin-(1-7)
Normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a biologically active endogenous angiotensin peptide that may play an important role in regulation of blood pressure.
Study: NCT06482853
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline will be used as the placebo comparator.
Study: NCT06477952
Drug: Dronabinol
Normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open label Dronabinol treatment for two weeks.
Study: NCT05062200
Drug: JNJ-77242113
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-77242113 will be administered as an oral tablet.
Study: NCT05479487
Drug: Fluzoparib+Apatinib
Normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluzoparib 100mg bid+ Apatinib 375mg qd
Study: NCT05479487
Drug: Fluzoparib Monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Fluzoparib (DB15637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluzoparib 150mg bid
Study: NCT05132985
Drug: Icotinib
Normalized name: icotinib
DrugBank: Icotinib (DB11737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125mg 1tt(Take 1 tablet 3 times a day) orally.
Study: NCT05132985
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2 (IV，Q3W)
Study: NCT05132985
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 5 (IV, Q3W)
Study: NCT05132985
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg/m2 (IV, Q3W)
Study: NCT05062876
Drug: AD-214
Normalized name: AD-214
DrugBank: AD-214 (DB18412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet administered before the breakfast during 7 days
Study: NCT05062876
Drug: AD-2141
Normalized name: Stahist AD
DrugBank: AD-214 (DB18412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet administered before the breakfast during 7 days
Study: NCT06178523
Drug: Sildenafil Citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil Acetate (Viagra®) 25 mg as a vaginal tablet 6 hourly for 10 days starting from the fifth day of the menstrual cycle (Group-A).
Study: NCT06081829
Drug: Ivosidenib
Normalized name: ivosidenib
DrugBank: Ivosidenib (DB14568)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will take 2 tablets (500 mg total) orally once daily.
Study: NCT06387407
Drug: Dabigatran Etexilate 150mg
Normalized name: DABIGATRAN ETEXILATE 150MG CAP,ORAL
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral dabigatran etexilate capsules, 150 mg twice a day.
Study: NCT04705714
Drug: Frankincense Extract
Normalized name: frankincense extract
DrugBank: Frankincense (DB16592)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The phytochemical composition of the volatile components of the extract was identified by GC-MS analysis, Crystal violet assay to test inhibition of biofilm formation by the tested isolates,Light microscope and scanning electron microscope were used to examine the biofilms and they confirmed the reduction of biofilm formation by frankincense extract
Study: NCT04661709
Drug: Wen Xin granule
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one dose daily, two times per day.
Study: NCT04661709
Drug: Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet
Normalized name: Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: one tablet daily. (for patients who can't use aspirin)
Study: NCT04661709
Drug: Atorvastatin Calcium
Normalized name: Atorvastatin Calcium
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg tablet, one tablet each night.
Study: NCT04661709
Drug: Isosorbide Mononitrate Tab 20 MG
Normalized name: isosorbide mononitrate 20 MG
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one tablet， twice daily.
Study: NCT04661709
Drug: Metoprolol Tartrate Tab 25 MG
Normalized name: Metoprolol Tartrate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12.5 mg or 25 mg, two times daily.
Study: NCT04661709
Drug: Aspirin Enteric-coated Tablets
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg tablet, one tablet daily.
Study: NCT04661709
Drug: Trimetazidine Dihydrochloride Tablets
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tablet, one tablet three times daily.
Study: NCT04661709
Drug: glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: be taken when angina pectoris attacks.
Study: NCT06518291
Drug: Nitrofurantoin 100 MG
Normalized name: nitrofurantoin 100 MG
DrugBank: Nitrofurantoin (DB00698)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparing two drugs in UTI treatment
Study: NCT06518291
Drug: Fosfomycin
Normalized name: FOSFOMYCIN
DrugBank: Fosfomycin (DB00828)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: treatment of UTI
Study: NCT04646837
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab 1000 mg IV Q3W for 2 cycle + Followed by adjuvant treatment for 1 year with Durvalumab 1000 mg IV Q3W for 4 months and Durvalumab 1500mg Q4W for 8 months
Study: NCT04646837
Drug: Albumin Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Albumin Paclitaxel 200-260 mg, depending on the patient's physical condition, for 2 cycle
Study: NCT05848011
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel Injection is a cytotoxic anticancer drug approved to treat prostate cancer
Study: NCT05848011
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A corticosteroid drug approved for use with docetaxel in the treatment of prostate cancer
Study: NCT04646837
Drug: Carboplatin/Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carboplatin AUC 6 IV Q3W or Cisplatin 80mg/㎡ for 2 cycle
Study: NCT00002378
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00002378
Drug: Nelfinavir mesylate
Normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002378
Drug: Saquinavir
Normalized name: Saquinavir
DrugBank: Saquinavir (DB01232)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002378
Drug: Delavirdine mesylate
Normalized name: Delavirdine Mesylate
DrugBank: Delavirdine (DB00705)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002378
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00002378
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002378
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04262687
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130 mg/m² by IV infusion over 2 hours, on day 1 of each cycle
Study: NCT04262687
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 7.5 mg/kg by IV infusion over 60 minutes, on day 1 of each cycle
Study: NCT04262687
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg by IV infusion over 30 minutes, on day 1 of each cycle
Study: NCT06234722
Drug: Very Low Nicotine Cigarette
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be assigned to one of two investigational cigarette nicotine levels for the duration of the experiment: 0.4mg/g or 15.8mg/g